InMed and Mentari merge in $290M deal to tackle migraine treatment gaps
What's the deal? InMed Pharmaceuticals (NASDAQ: INM), a Vancouver-based biotech, is merging with Mentari Therapeutics, a startup focused on migraine prevention therapies. The combined entity will trade on the Nasdaq Capital Market under the Mentari Therapeutics name. A concurrent private placement targets roughly $290 million in gross proceeds to fund operations through 2028.
The deal centres on Mentari's two lead drug candidates: MT-001, an anti-PACAP monoclonal antibody, and MT-002, which targets both the CGRP and PACAP pathways. Both aim to help the roughly two-thirds of migraine patients who don't respond well to existing anti-CGRP treatments.
Why now? Current migraine therapies leave a large share of patients underserved. Recent studies on the PACAP pathway have generated significant interest, suggesting a new angle of attack. Mentari's dual-pathway approach could offer a step change in treatment — but it needs capital and a public-market framework to push its candidates through clinical trials.
MT-002 is expected to produce Phase 1 healthy volunteer trial results by 2027, with MT-001's Phase 2a proof-of-concept data projected for 2028.
What could go wrong? Both drug candidates are early-stage. Promising in vitro potency doesn't guarantee clinical success, and the timeline to commercialisation stretches years into the future. The $290 million raise also means substantial dilution for existing InMed shareholders, even as the company pivots away from its cannabinoid-therapy roots.
Migraine treatment is a competitive space. If larger pharma companies advance their own PACAP-targeting therapies faster, Mentari's edge could shrink.
The signal: This merger reflects a broader trend of small-cap biotechs using reverse-merger-style deals to access public markets and fund ambitious pipelines. It also underscores growing investor appetite for next-generation migraine treatments that go beyond the current CGRP-focused standard of care.
Eric Adams, InMed's chief executive officer, called the deal "an incredible opportunity" to engage with a pipeline that has "substantial therapeutic and commercial promise." Mentari's board chair Julie Bruno said the transaction provides the capital needed to compete in a rapidly evolving landscape.
Read more: third-news.com
